BACKGROUND: We have demonstrated that donor cell chimerism is associated with a lower incidence of obliterative bronchiolitis (OB) in lung recipients, and that donor chimerism is augmented by the infusion of donor bone marrow (BM). We herein report the intermediate results of a trial combining the infusion of donor BM and lung transplantation. METHODS: Clinical and in vitro data of 26 lung recipients receiving concurrent infusion of donor bone marrow (3.0 to 6.0 x 10(8) cells/kg) were compared with those of 13 patients receiving lung transplant alone. RESULTS: Patient survival and freedom from acute rejection were similar between groups. Of the patients whose graft survived greater than 4 months, 5% (1 of 22) of BM and 33% (4 of 12) of control patients, developed histologic evidence of OB (p = 0.04). A higher proportion (but not statistically significant) of BM recipients (7 of 10, 70%) exhibited donor-specific hyporeactivity by mixed lymphocyte reaction assays as compared with the controls (2 of 7, 28%). CONCLUSIONS: Infusion of donor BM at the time of lung transplantation is safe, and is associated with recipients' immune modulation and a lower rate of obliterative bronchiolitis.
BACKGROUND: We have demonstrated that donor cell chimerism is associated with a lower incidence of obliterative bronchiolitis (OB) in lung recipients, and that donor chimerism is augmented by the infusion of donor bone marrow (BM). We herein report the intermediate results of a trial combining the infusion of donor BM and lung transplantation. METHODS: Clinical and in vitro data of 26 lung recipients receiving concurrent infusion of donor bone marrow (3.0 to 6.0 x 10(8) cells/kg) were compared with those of 13 patients receiving lung transplant alone. RESULTS:Patient survival and freedom from acute rejection were similar between groups. Of the patients whose graft survived greater than 4 months, 5% (1 of 22) of BM and 33% (4 of 12) of control patients, developed histologic evidence of OB (p = 0.04). A higher proportion (but not statistically significant) of BM recipients (7 of 10, 70%) exhibited donor-specific hyporeactivity by mixed lymphocyte reaction assays as compared with the controls (2 of 7, 28%). CONCLUSIONS: Infusion of donor BM at the time of lung transplantation is safe, and is associated with recipients' immune modulation and a lower rate of obliterative bronchiolitis.
Authors: J Miller; J Mathew; R Garcia-Morales; K E Zucker; M Carreno; Y Jin; L Fuller; G W Burke; G Ciancio; A G Tzakis; C Ricordi; L Olson; A Rosen; D Roth; V Esquenazi Journal: Transplantation Date: 1999-10-27 Impact factor: 4.939
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: R Garcia-Morales; M Carreno; J Mathew; K Zucker; R Cirocco; G Ciancio; G Burke; D Roth; D Temple; A Rosen; L Fuller; V Esquenazi; T Karatzas; C Ricordi; A Tzakis; J Miller Journal: J Clin Invest Date: 1997-03-01 Impact factor: 14.808
Authors: C Ricordi; T Karatzas; J Nery; M Webb; G Selvaggi; L Fernandez; F A Khan; P Ruiz; E Schiff; L Olson; H Fernandez; J Bean; V Esquenazi; J Miller; A G Tzakis Journal: Transplantation Date: 1997-01-15 Impact factor: 4.939
Authors: A Zeevi; M Pavlick; S Lombardozzi; R Banas; O Pappo; A S Rao; P Fontes; J Demetris; R Shapiro; F Dodson Journal: Transplantation Date: 1995-02-27 Impact factor: 4.939
Authors: T E Starzl; A J Demetris; M Trucco; H Ramos; A Zeevi; W A Rudert; M Kocova; C Ricordi; S Ildstad; N Murase Journal: Lancet Date: 1992-10-10 Impact factor: 79.321
Authors: H J Schlitt; J Hundrieser; M Hisanaga; K Uthoff; M Karck; T Wahlers; K Wonigeit; R Pichlmayr Journal: Lancet Date: 1994-06-11 Impact factor: 79.321
Authors: T E Starzl; A J Demetris; M Trucco; A Zeevi; H Ramos; P Terasaki; W A Rudert; M Kocova; C Ricordi; S Ildstad Journal: Transplantation Date: 1993-06 Impact factor: 4.939
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119
Authors: Outi E Päiväniemi; Petra Musilova; Peter M Raivio; Paula K Maasilta; Hanni S Alho; Jiri Rubes; Kristiina Aittomäki; Ulla-Stina Salminen Journal: Respir Res Date: 2011-04-26